miR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy

Cancer Prevention Research

Volumn 7, Issue 6, 2014, Pages 607-616

  Wang, Zhen Hua ^a   Ren, Lin Lin ^a   Zheng, Ping ^b   Zheng, Hai Ming ^b   Yu, Ya Nan ^a   Wang, Ji Lin ^a   Lin, Yan Wei ^a   Chen, Ying Xuan ^a   Ge, Zhi Zheng ^a   Chen, Xiao Yu ^a   Hong, Jie ^a   Fang, Jing Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 194; UNCLASSIFIED DRUG; MIRN194 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; COHORT ANALYSIS; COLORECTAL ADENOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPECTOMY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; ABDOMINAL SURGERY; ADENOMA; AGED; COLORECTAL NEOPLASMS; DISEASE COURSE; INTESTINAL POLYPS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE PROGRESSION; FEMALE; HUMANS; INTESTINAL POLYPS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84903552631     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0426     Document Type: Article

References (29)

1. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81. (Pubitemid 24015040)
2. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-7.
3. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143: 844-57.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
5. Martinez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza E, Winawer SJ, et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 2009;136: 832-41.
6. Lieberman DA, Holub J, Eisen G, Kraemer D, Morris CD. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc 2005;62:875-83. (Pubitemid 41654422)
7. Brand L, Munding J, Pox CP, Ziebarth W, Reiser M, Huppe D, et al. β-catenin, Cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy. Int J Colorectal Dis 2013;28:1091-8.
8. Barry EL, Poole EM, Baron JA, Makar KW, Mott LA, Sandler RS, et al. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. Cancer Causes Control 2013;24:47-54.
9. Murphy G, Sansbury LB, Cross AJ, Stolzenberg-Solomon R, Laiyemo A, Albert PS, et al. Folate and MTHFR: risk of adenoma recurrence in the Polyp Prevention Trial. Cancer Causes Control 2008;19:751-8.
10. Bobe G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Colburn NH, et al. Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res 2010;3:764-75.
11. Levine AJ, Wallace K, Tsang S, Haile RW, Saibil F, Ahnen D, et al. MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial. Cancer Epidemiol Biomarkers Prev 2008;17:2409-15.
12. Murphy G, Cross AJ, Sansbury LS, Bergen A, Laiyemo AO, Albert PS, et al. Dopamine D2 receptor polymorphisms and adenoma recurrence in the Polyp Prevention Trial. Int J Cancer 2009;124: 2148-51.
13. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
14. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008;455:64-71.
15. Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 2012;61:1447-53.
16. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, et al. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 2012;19:3065-71.
17. Nishida N, Yokobori T, Mimori K, Sudo T, Tanaka F, Shibata K, et al. MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol 2011;38:1437-43.
18. Waldman SA, Terzic A. Translating MicroRNA discovery into clinical biomarkers in cancer. JAMA 2007;297:1923-5. (Pubitemid 46707848)
19. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89.
20. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907. (Pubitemid 351449681)
21. Li W, Xie L, He X, Li J, Tu K, Wei L, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008;123:1616-22.
22. Chiang Y, Song Y, Wang Z, Liu Z, Gao P, Liang J, et al. microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med 2012;3:560-6.
23. Song Y, Zhao F, Wang Z, Liu Z, Chiang Y, Xu Y, et al. Inverse association between miR-194 expression and tumor invasion in gastric cancer. Ann Surg Oncol 2012;19 Suppl 3:S509-17.
24. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18:367-81.
25. Sundaram P, Hultine S, Smith LM, Dews M, Fox JL, Biyashev D, et al. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res 2011;71:7490-501.
26. Hino K, Tsuchiya K, Fukao T, Kiga K, Okamoto R, Kanai T, et al. Inducible expression of microRNA-194 is regulated by HNF-1alpha during intestinal epithelial cell differentiation. RNA 2008;14:1433-42. (Pubitemid 351872199)
27. Chen H1, Miao R, Fan J, Han Z, Wu J, Qiu G, et al. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin Exp Metastasis 2013;30:651-8.
28. Hall JS, Taylor J, Valentine HR, Irlam JJ, Eustace A, Hoskin PJ, et al. Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer 2012;107:684-94.
29. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007;13:1668-74. (Pubitemid 47481675)